

Decoding STK11 in Lung Cancer Therapy Show Notes

Explore the critical role of biomarker testing in lung cancer treatment with Dr. Salman Punekar, Medical Oncologist at NYU Langone Health. Specializing in early-phase clinical development, Dr. Punekar explains the function of the biomarker STK11, a newer discovery shaping approaches to non-small cell lung cancer therapies.

Guests

Salman R. Punekar, MD

Assistant Professor of Medicine of Medical Oncology at NYU Langone Health.

Specialization in early-phase clinical development and translational research.



Stephanie Williams

Lung Cancer survivor. In March of 2021, Stephanie Williams had a mild cough with some wheezing. She assumed it was allergies. This lingering cough didn't go away, so Stephanie brought it up at her regular appointment. When her doctor ordered a chest X-ray, they revealed a mass.



Resources:

- Learn more about STK11
- Unraveling the Role of STK11/LKB1 in Non-small Cell Lung Cancer PM

LCFA's mission is the improvement in survivorship of lung cancer patients through the funding of transformative science.



While raising funds to support lung cancer research, LCFA will raise the public's awareness and serve as a resource for patients or anyone seeking answers, hope, and access to updated treatment information, scientific investigation, and clinical trials.

You can also join the conversation with LCFA on Facebook, Twitter, and Instagram.